Avascular Necrosis Treatment & Management
- Author: Jeanne K Tofferi, MD, MPH, FACP; Chief Editor: Herbert S Diamond, MD more...
Medical management of avascular necrosis (AVN) primarily depends on the location and severity of disease, as well as the patient's age and general health. Treatment outcomes correlate directly with the stage of the disease. No medical treatment has proven effective in preventing or arresting the disease process. In all patients, establish a firm diagnosis and exclude other conditions such as infections (osteomyelitis) and tumors.
Conservative measures include limited weight bearing with crutches and pain medications. This may be beneficial and is a reasonable initial course of action if the involved segment is smaller than 15% and far from the weight-bearing region. Immobilization may be helpful in some cases (eg, AVN of the distal femur or tibia). In advanced AVN, the disease course is unaffected by activity and will eventually require surgery.
Treatment with bisphosphonates may be helpful. Although large-scale, randomized, double-blind studies have not been performed, a systematic review of eight articles involving 788 hips suggested that alendronate has short-term efficacy in reducing pain, improving articular function, slowing of bone collapse progression, and delaying the need for total hip arthroplasty in adults with AVN
Statin therapy to prevent corticosteroid-induced AVN may be helpful. Pritchett reported a 1% incidence of AVN in 284 patients who were on statin therapy during the entire period of corticosteroid treatment (average, 7.5 y). The use of high-dose corticosteroids carries a reported 3-20% incidence of AVN.
Extracorporeal shockwave therapy (ESWT) has shown beneficial effects in early AVN of the femoral head. ESWT may relieve pain and improve hip function of the hip, and induce regression of AVN.[19, 20] ESWT may be combined with alendronate therapy.
Several surgical procedures have been used in an attempt to treat AVN, with variable success. No surgical procedure is the consensual best among surgeons in the treatment of AVN. In early stages of AVN (precollapse), core decompression with or without bone graft is typically considered the most appropriate treatment. In late stages, characterized by collapse, femoral head deformity, and secondary osteoarthritis, total hip arthroplasty is the most appropriate treatment.
Researchers postulate that core decompression improves circulation by decreasing intramedullary pressure and preventing further ischemia and progressive joint destruction. The best results vary from 34-95%, which is significantly better than results of conservative treatment. The best results are obtained when treating patients with early AVN (precollapse). Core decompression is also effective for pain control.
Bone graft options include structural cortical or medullary bone graft and vascularized bone graft with either a muscle-pedicle bone graft or free vascularized fibular graft.
Bone grafting is combined with the following:
Core decompression, which may interrupt the cycle of ischemia
Excision of sequestrum, which may inhibit revascularization of the femoral head
Period of limited weight bearing
The best results have been reported with free vascularized bone grafts. Success rates of 70% and 91% have been reported in two small series.[23, 24]
Advantages of free vascularized grafts compared with total hip arthroplasty include the following:
Healed femoral head may allow more activity
No foreign body–associated complications occur
If performed during early AVN, lifelong survival of the femoral head is possible
The patient has the option of total hip arthroplasty in the future
Disadvantages of free vascularized grafts include the following:
Longer period of recovery
Less complete pain relief
Variable success rate
Lack of effectiveness in advanced disease
In a review of bone grafting through a window at the femoral head-neck junction, Zuo et al found that factors predicting good clinical success were absence of femoral head collapse or degree of collapse <2 mm (Association Research Circulation Osseous [ARCO] stage IIIa). Surgical failure rates were high in patients with femoral head collapse >2 mm (ARCO stage IIIb and IIIc) and in those with necrotic lesions involving the lateral pillar (L2 and L3 type). Finally, patients 40 years of age and older had a worse prognosis than those younger than 40.
Several osteotomy procedures have been tried with variable success.
Intertrochanteric osteotomies have been performed in patients with posttraumatic AVN.
Transtrochanteric rotational osteotomy involves rotation of the femoral head and neck on the longitudinal axis. The necrotic anterosuperior part of the femoral head becomes posterior, and the weight-bearing force is transmitted to what was previously the posterior articular surface, which is not involved in the ischemic process. In 1992, Sugano and colleagues reported excellent results in 56% of patients who underwent this procedure. Transtrochanteric rotational osteotomy is technically demanding.
Total hip arthroplasty
Most patients with advanced disease (stage III and above) require total hip arthroplasty. Total hip arthroplasty provides excellent pain relief for many years, although most young patients require repeat surgery. With high failure rates (10-50% after 5 y), patients with AVN will probably need a second total hip arthroplasty during their lifetime.
Cheung et al reported excellent long-term survival of cementless total hip arthroplasty for managing AVN of the hip. In their review of 182 total hip arthroplasties 117 of them for AVN, 19.1- year survival was 97.1% for AVN patients and 96.2% for non-AVN patients.
AVN of the femoral condyles (knees) may respond to more conservative intervention such as arthroscopic lavage and debridement. AVN of the femoral condyles has a better prognosis than hip AVN, although osteoarthritis eventually develops.
The use of stem cells implanted via core decompression has been studied for the treatment of early-stage (precollapse) AVN of the femoral head.[28, 29, 30] Despite encouraging results in early studies, clinical benefits have been inconsistent, and the procedure remains controversial.
Obtain consultation with an orthopedic surgeon. Early intervention can save affected joints and obviate the need for joint replacement.
In early AVN, patients should use crutches or other supports to avoid weight bearing. In advanced AVN, the disease course is unaffected by activity; surgery is the only option.
Bose VC, Baruah BD. Resurfacing arthroplasty of the hip for avascular necrosis of the femoral head: a minimum follow-up of four years. J Bone Joint Surg Br. 2010 Jul. 92(7):922-8. [Medline].
Steffen RT, Athanasou NA, Gill HS, Murray DW. Avascular necrosis associated with fracture of the femoral neck after hip resurfacing: histological assessment of femoral bone from retrieval specimens. J Bone Joint Surg Br. 2010 Jun. 92(6):787-93. [Medline].
Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16. 144(10):753-61. [Medline].
Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014 Apr. 19(2):403-10. [Medline].
Kawai K, Tamaki A, Hirohata K. Steroid-induced accumulation of lipid in the osteocytes of the rabbit femoral head. A histochemical and electron microscopic study. J Bone Joint Surg Am. 1985 Jun. 67(5):755-63. [Medline].
Wang GJ, Sweet DE, Reger SI, et al. Fat-cell changes as a mechanism of avascular necrosis of the femoral head in cortisone-treated rabbits. J Bone Joint Surg Am. 1977 Sep. 59(6):729-35. [Medline].
Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005 Feb. 34(2):120-3. [Medline].
Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2009 Mar. 36(3):478-90. [Medline].
Ninomiya S. An epidemiological survey of idiopathic avascular necrosis of the femoral head in Japan. Annual Report of Japanese Investigation Committee for Intractable Disease. 1989.
Aaron RK, Voisinet A, Racine J, Ali Y, Feller ER. Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Ann N Y Acad Sci. 2011 Dec. 1240(1):38-46. [Medline].
Lawson-Ayayi S, Bonnet F, Bernardin E, et al. Avascular necrosis in HIV-infected patients: a case-control study from the Aquitaine Cohort, 1997-2002, France. Clin Infect Dis. 2005 Apr 15. 40(8):1188-93. [Medline].
Mehta P, Nelson M, Brand A, Boag F. Avascular necrosis in HIV. Rheumatol Int. 2013 Jan. 33(1):235-8. [Medline].
Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990 Dec. 89(6):733-8. [Medline].
Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case-control study. Bone. 1998 Jan. 22(1):67-71. [Medline].
Diz P, López-Cedrún JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012 Sep. 143(9):981-4. [Medline].
[Guideline] Murphey MD, Roberts CC, Bencardino JT, Appel M, Arnold E, Chang EY, et al. ACR Appropriateness Criteria Osteonecrosis of the Hip. J Am Coll Radiol. 2016 Feb. 13 (2):147-55. [Medline].
Luo RB, Lin T, Zhong HM, Yan SG, Wang JA. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Med Sci Monit. 2014 Nov 26. 20:2439-47. [Medline].
Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop. 2001 May. (386):173-8. [Medline].
Wang CJ, Cheng JH, Huang CC, Yip HK, Russo S. Extracorporeal shockwave therapy for avascular necrosis of femoral head. Int J Surg. 2015 Dec. 24 (Pt B):184-7. [Medline].
Gao F, Sun W, Li Z, Guo W, Wang W, Cheng L, et al. High-Energy Extracorporeal Shock Wave for Early Stage Osteonecrosis of the Femoral Head: A Single-Center Case Series. Evid Based Complement Alternat Med. 2015. 2015:468090. [Medline].
Van Laere C, Mulier M, Simon JP, et al. Core decompression for avascular necrosis of the femoral head. Acta Orthop Belg. 1998 Sep. 64(3):269-72. [Medline].
Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: role of vascularized bone grafts. Orthop Clin North Am. 2007 Jan. 38(1):13-22, v. [Medline].
Hasegawa Y, Iwata H, Torii S, et al. Vascularized pedicle bone-grafting for nontraumatic avascular necrosis of the femoral head. A 5- to 11-year follow-up. Arch Orthop Trauma Surg. 1997. 116(5):251-8. [Medline].
Urbaniak JR, Coogan PG, Gunneson EB, et al. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. 1995 May. 77(5):681-94. [Medline].
Zuo W, Sun W, Zhao D, Gao F, Su Y, Li Z. Investigating Clinical Failure of Bone Grafting through a Window at the Femoral Head Neck Junction Surgery for the Treatment of Osteonecrosis of the Femoral Head. PLoS One. 2016. 11 (6):e0156903. [Medline]. [Full Text].
Sugano N, Takaoka K, Ohzono K, et al. Rotational osteotomy for non-traumatic avascular necrosis of the femoral head. J Bone Joint Surg Br. 1992 Sep. 74(5):734-9. [Medline].
Cheung KW, Chiu KH, Chung KY. Long-term result of cementless femoral stem in avascular necrosis of the hip. Hip Int. 2014 Sep 1. [Medline].
Gangji V, Hauzeur JP. Cellular-based therapy for osteonecrosis. Orthop Clin North Am. 2009 Apr. 40(2):213-21. [Medline].
Lau RL, Perruccio AV, Evans HM, Mahomed SR, Mahomed NN, Gandhi R. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskelet Disord. 2014 May 16. 15:156. [Medline]. [Full Text].
Hernigou P, Trousselier M, Roubineau F, Bouthors C, Chevallier N, Rouard H, et al. Stem Cell Therapy for the Treatment of Hip Osteonecrosis: A 30-Year Review of Progress. Clin Orthop Surg. 2016 Mar. 8 (1):1-8. [Medline]. [Full Text].
Goker B, Block JA. Risk of contralateral avascular necrosis (AVN) after total hip arthroplasty (THA) for non-traumatic AVN. Rheumatol Int. 2006 Jan. 26(3):215-9. [Medline].
Agarwala S, Jain D, Joshi VR, et al. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005 Mar. 44(3):352-9. [Medline].
Lai KA, Shen WJ, Yang CY, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005 Oct. 87(10):2155-9. [Medline].
[Guideline] Aldridge JM 3rd, Urbaniak JR. Avascular necrosis of the femoral head: etiology, pathophysiology, classification, and current treatment guidelines. Am J Orthop. 2004 Jul. 33(7):327-32. [Medline].
Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):61-70. [Medline].
Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):75-84. [Medline].
Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002 Oct. 32(2):94-124. [Medline].
Bachiller FG, Caballer AP, Portal LF. Avascular necrosis of the femoral head after femoral neck fracture. Clin Orthop Relat Res. 2002 Jun. 87-109. [Medline].
Bernasek TL, Stahl JL, Pupello D. Pyrolytic carbon endoprosthetic replacement for osteonecrosis and femoral fracture of the hip: a pilot study. Clin Orthop Relat Res. 2009 Jul. 467(7):1826-32. [Medline]. [Full Text].
Dodson TB. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):44-52. [Medline].
Dudkiewicz I, Covo A, Salai M, et al. Total hip arthroplasty after avascular necrosis of the femoral head: does etiology affect the results?. Arch Orthop Trauma Surg. 2004 Mar. 124(2):82-5. [Medline].
Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):96-106. [Medline].
Gliklich R, Wilson J. Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry. J Oral Maxillofac Surg. 2009 May. 67(5 Suppl):71-4. [Medline].
Hasse B, Ledergerber B, Egger M, Flepp M, Bachmann S, Bernasconi E, et al. Antiretroviral treatment and osteonecrosis in patients of the Swiss HIV Cohort Study: a nested case-control study. AIDS Res Hum Retroviruses. 2004 Sep. 20(9):909-15. [Medline].
Jones LC, Hungerford MW, Khanuja HS, Hungerford DS. Outcome measures for evaluation of treatments for osteonecrosis. Orthop Clin North Am. 2009 Apr. 40(2):179-91. [Medline].
Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009 Jun. 67(6):1167-73. [Medline].
Martí-Carvajal AJ, Solà I, Agreda-Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2014 Jul 10. 7:CD004344. [Medline].
Roposch A, Stöhr KK, Dobson M. The effect of the femoral head ossific nucleus in the treatment of developmental dysplasia of the hip. A meta-analysis. J Bone Joint Surg Am. 2009 Apr. 91(4):911-8. [Medline].
|Stage||Clinical and Laboratory Findings|